Objectives: This study compared the prevalence and intensity of symptoms and the health-related quality of life (HQL) of patients taking antihypertensive medications and patients without disease. Methods: This cross-sectional study used surveys mailed to patient's homes. All consecutive patients over age 30 years attending either a general medicine or hypertension clinic during 3 months were eligible (n ‫؍‬ 437). Hypertension group (HTN-G) patients were diagnosed with primary hypertension, prescribed antihypertensive medications, and had no other symptomatic conditions or drug therapies. Control group (CNTL-G) patients were seen in the general medicine clinic and had no chronic symptomatic conditions or drug therapies. Measures included the Symptom Distress Checklist (SDC, list of 51 symptoms, frequency, and level of distress), the Medical Outcomes Study Short Form-36 (SF-36), medications, blood pressures, and other data obtained from medical records and patient self-report. Results: A total of 222 patients responded (46% CNTL-G, 55% HTN-G) . HTN-G patients were somewhat older (59.0 ؎ 11.2 vs 48.5 ؎ 11.7 years, P ‫؍‬ 0.001) and had a higher percent of minorities (24.8% vs 13.5%, P ‫؍‬ 0.02), but otherwise similar. After adjusting for age and race differences, HTN-G patients reported significantly more symptoms (8. 8 ؎ 7.8 vs 4.7 ؎ 4.8, P ‫؍‬ 0.001) and related  distress (32.2 ؎ 4.2 vs 12.0 ؎ 18.2, P ‫؍‬ 0.001) as well as lower scores (reduced HQL) for most of the SF-36 domains. In general, hypertensive patients had more physical, but not mental symptoms than control patients. Conclusions: Hypertensive patients receiving antihypertensive medications have more symptoms and lower HQL. Differences were detected by both a brief, general HQL instrument and a detailed, disease-specific instrument. Routine screening of treated hypertensive patients using a brief HQL questionnaire to detect physical symptoms may prove feasible and useful.
Introduction
Patients seen in the primary care setting often present with symptoms, regardless of their medical problems. Many of these symptoms are vague and general in nature. In the case of hypertension, symptoms are frequently reported by hypertensive patients that are also reported by normotensive patients. 1 Although hypertension is thought to be asymptomatic, cognitive changes, mood alterations, and general symptoms such as dizziness and head-ache attributable to hypertension have been described. [2] [3] [4] [5] [6] [7] Some symptoms are unique to antihypertensive medications, but overlap with symptoms described or attributed to the disease of hypertension as well as the general symptoms seen in a primary care population. Symptoms, whether disease or treatment induced, may impair the health-related quality of life of patients. Health-related quality of life (HQL) refers to the physical, emotional, and social impact of disease and treatments 8, 9 and is distinct from physiologic measures of disease. [8] [9] [10] [11] HQL measures may reflect disease or treatment characteristics that are not captured by clinical symptom measures and also may be an efficient way to represent the disease and treatment impact from the patient's perceptive.
The purpose of this study was to describe the Journal of Human Hypertension prevalence of symptoms, the amount of distress caused by the symptoms, and the HQL of patients with treated, uncomplicated hypertension, compared to relatively healthy patients. The research was based on a model relating clinical variables with HQL described by Wilson and Cleary. 12 The model proposes that a relationship exists between symptoms and functional status (HQL). We hypothesised that hypertensive patients taking antihypertensive medications would have more symptoms, greater distress associated with the symptoms and lower HQL compared to healthy patients. Specifically, we hypothesised that the greatest differences would occur in measures of physical functioning, vitality and depressive symptoms.
Research design and methods

Study setting and patient population
The study was a cross-sectional design of two cohorts of patients who attended either a university general medicine clinic or a hypertension clinic. Patients in the hypertensive group had a diagnosis of hypertension and were prescribed one or more antihypertensive medications. Patients in the control group were healthy without symptomatic diseases or treatments. A cohort design, comparing hypertensive and non-hypertensive patients, was chosen rather than a case-control design in which non-hypertensive controls could be matched with cases on selected characteristics, since: (a) little information was available to determine which characteristics should be matched, (b) potential differences between the two populations could be addressed through multivariate modelling, and (c) adequate power to detect a meaningful difference between the groups could be achieved more readily using a cohort design.
Subjects for both groups were initially identified through a computerised data search of the medical practice billing data. Patients in the hypertensive group were identified after searching the internal medicine and the hypertension clinic billing database for encounters with the ICD-9 diagnosis code for essential hypertension. Subjects for the control group were chosen from the general medicine clinic population with the ICD-9 diagnosis code for wellperson checkup. The database was searched for all patients from July through December 1996. The medical records of the identified patients were reviewed to identify those meeting the study criteria.
Patients greater than 30 years old were included. Inclusion into the hypertensive group required the documented diagnosis of essential hypertension and medication treatment for hypertension. Inclusion into the control group required the absence of documented diagnosis of hypertension. Patients were excluded from both groups if they had other symptomatic chronic disease states such as pulmonary dis-ease (asthma and chronic obstructive pulmonary diseases), inflammatory rheumatic diseases, congestive heart failure (documented New York Heart Classification grades III or IV), chronic pain syndromes, neurologic disorders or deficits, ischaemic heart disease, diabetes mellitus, and others. Patients were excluded if they had medical problems that interfered with their ability to participate in the study such as terminal illness, dementia, and severe functional impairment, as determined by medical record. Finally, patients in the hypertensive group were excluded if evidence of hypertension-related target organ damage was present (documentation of ophthalmic changes, renal changes such as elevated serum creatinine greater than 2.0 mg/dL or albuminuria, congestive heart failure, or stroke). Documentation of left ventricular hypertrophy in the medical record was an exclusion criteria. However, left ventricular hypertrophy was not universally assessed and could not be ruled out for this study for all patients. The study was reviewed and approved by the Institutional Review Board of the university.
The desired total number of respondents was 120 (60 in each group) as calculated by power analysis to identify difference in prevalence of a characteristic between the two groups of approximately 20% with power ϭ 0.80, with an alpha level of 0.05. Assuming an 80% response rate, a sample of 150 patients would be adequate. However, to ensure an adequate number of respondents, a sample of 400 patients was obtained.
Measurements
Patient-related data were obtained from a selfadministered questionnaire which included age, gender, race, income, education, and self-reported length of diagnosis of hypertension. Information was also collected on medications including drug name, strength, and dose as well as length of current therapy.
Symptoms were identified using a modified Symptom Distress Checklist (SDC), a questionnaire developed for use in clinical trials to identify the existence of antihypertensive drug adverse effects and the impact they have on patients. [13] [14] [15] The modified SDC consists of a list of 51 symptoms often related to antihypertensive drug side effects. The questionnaire asks whether the patient experienced the symptom in the last 4 weeks (yes/no), the frequency of the problem in the past four weeks (four response categories ranging from once or twice to daily or more often), and the extent to which it caused distress (five response categories ranging from little or none to extreme). The distress level for each reported symptom was calculated from the product of the frequency of occurrence of the symptom during the previous 4 weeks and the level of reported distress. Appendix 1 lists the individual symptoms. Three summary measures were calcu-lated from the SDC symptoms. These included the sum of the number of symptoms reported (SDC frequency) per patient; the sum of the number of symptoms that caused distress (SDC distress frequency); and the total distress level of reported symptoms (symptom distress level or SDL), calculated as the sum of the product of the frequency of the reported distressful symptom and the distress level of each reported symptom per patient. The original developmental work on the SDC identified groupings of 14 symptom factors from the original 49 symptoms. 14 Two of the 14 symptom factors were 'mixed', comprised of symptoms that are not clinically related. Two additional symptoms related to sexual functioning were added for this study, for a total of 15 symptom factors. Appendix 1 lists the individual symptoms grouped by symptom factor. Frequency of occurrence of each factor was determined by the number of times that at least one of the factor's component symptoms was mentioned by the patient. For example, for a symptom factor comprised of three symptoms, if one or more is indicated as being present by the patient, the symptom factor is noted as being present. No weighting factor was used if more than one component factor was indicated as present. The distress level for each symptom factor was calculated as the mean distress level associated with the component symptoms reported by the patient.
The SF-36 Health Survey (SF-36), Version 1.0 (The Health Institute, New England Medical Center, USA) 16 was used to assess general HQL. The SF-36 is a validated 36-item questionnaire that measures the health concepts of physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social function, role limitations due to emotional problems, and mental health. It also contains a single item that examines change in health over time. Final scoring of the questionnaire data provides eight individual domain scores that can be further aggregated into two summary scores (physical and mental health summary). Scores can range from 100 (perfect health, optimal functional status) to 0 (worst health, poorest functional status). The scannable version of the SF-36 was used (Response Healthcare Information Management, Inc., East Greenwich, Rhode Island, USA).
Data were collected by self-administered questionnaires (Patient Questionnaire, SDC, SF-36) through mailings to the patients' homes. A followup reminder postcard was sent to non-respondents 2 weeks after the initial survey packet is sent. One month following the mailing of the first survey a second survey packet was sent to non-respondents. Telephone follow-up was attempted for non-respondents, but few patients were accessible during normal business hours.
Information on age, gender, race, blood pressure, other documented diseases and antihypertensive medications was collected from the medical records Journal of Human Hypertension for all study patients. Medication information included drug name, strength, and dose, which was compared to the self-reported treatment data. Systolic/diastolic blood pressures were recorded from the year preceding the study. The most recent blood pressures recorded in the medical record were used for analysis since there were no clinically significant differences between the mean and most recent systolic and diastolic blood pressures (the only statistically significant difference was in the hypertension group systolic blood pressure: most recent ϭ 140.3 mm Hg vs mean ϭ 143.7 mm Hg, P ϭ 0.001). Self-reported treatment information matched that found in the medical record for all patients. Data obtained from the medical record was used, in part, for a non-response bias assessment.
Data analysis
Patient characteristics, SDC summary scores, and SF-36 domain scores were compared between the hypertensive and control groups using Chi-squared tests for categorical and Student's t-test for unmatched samples for continuous variables. Ageand race-adjustments for SF-36 scales, SDC summary variables, and SDC factors were made using ANOVA. The resulting adjusted means are presented. Assessment of the influence of disease and blood pressure on symptom summary measures and SF-36 domain scores was assessed using ANOVA, comparing results of the following groups: the control group, hypertensives with blood pressures Ͻ140/90 mm Hg, and hypertensives with blood pressures у140/90 mm Hg.
Results
Of the 947 patients identified through billing codes, 438 patients met the inclusion criteria after chart review. These included 216 control group and 222 hypertensive group patients. Thirteen questionnaire packets were undeliverable (two in the hypertension group, 11 in the control group), leaving a sample of 425 patients (205 control, 220 hypertensive). A total of 225 (52.9% response rate) patients responded, of which 100 (48.8% response rate) were in the control group and 125 (56.8% response rate) were in the hypertensive group.
The non-response bias assessment showed no differences between respondents and non-respondents in either group for blood pressure or gender, as well as the number of prescribed antihypertensive entities for the hypertensive group. However, more patients above 65 years of age (48.5% vs 43.8%, respondents vs non-respondent, P ϭ 0.002, for control group; 58.9% vs 55.5%, respondents vs nonrespondents, P ϭ 0.03 for hypertensive group) and black patients (5.6% vs 17.6%, respondents vs nonrespondents, P ϭ 0.01 for control group; 17.1% vs 35.8%, respondents vs non-respondents, P ϭ 0.005, hypertensive group) tended not to respond in both groups. The hypertension group was somewhat older and had a higher percent of minorities responding than the control group (Table 1) . Blood pressures were, as expected, different between the two groups. Hypertensive patients tended to have had the disease for many years and had fairly stable medication regimens. The medication classes most commonly reported by hypertensive patients were diuretics (33.3%), followed by ACE-inhibitors (20.6%), betablockers (18.4%), and calcium channel blockers (15.8%). Other medications included peripheral alpha-blockers (terazosin, prazosin), central acting agents (clonidine and methyldopa), and direct acting agents (minoxidil). Patients took an average of between one and two antihypertensive medications. Table 2 presents the age-and race-adjusted SDC summary variable scores for the two groups. The hypertensive patients reported significantly more symptoms, more symptoms that caused distress, and a higher total distress level associated with the symptoms than controls. Table 3 presents the number of patients reporting each symptom factor. Bloating, breathing problems, dizziness, sexual problems, thirst, urinary symp- toms, weariness, and both mixed factors were all reported significantly more often in the hypertension group than the control group. Symptom factors that were prevalent in over 40% of each group but were without significant difference included mood and pain symptoms. Table 4 presents the between group comparison of the mean distress level associated with each symptom factor. This value was determined by calculating the mean distress level reported for the symptoms that comprise the symptom factor. Included in the calculation were symptoms that were reported as occurring but the patient indicated no associated distress. Symptom factors with significantly more distress occurring in the hypertensive group included breathing problems, dizziness, both mixed factors, pain, skin problems, urinary problems, and weariness. Sexual problems had the highest distress level reported in both groups but the difference between the groups was not statistically significant. Table 5 shows the age-and race-adjusted SF-36 scale (domain) scores for the two groups. In all scales (domains), patients in the hypertension group reported lower scores (worse function) than the normal control group. Statistically significant differences between groups were seen for the domains of bodily pain, general health, physical functioning, role-physical, social functioning, and vitality. No significant differences were observed for mental health, role-emotion, and the mental health summary score. Figure 1 is a graphic demonstration of the relationship between degree of blood pressure control and symptom characteristics. Patients in the control group, who were free of hypertension and had the lowest blood pressure reported the fewest number of symptoms and least distress associated with reported symptoms. Hypertensive patients were divided into two groups; those whose blood pressure was Ͻ140/90 mm Hg (blood pressure under control) and those у140/90 mm Hg (blood pressure not controlled). There is a distinct and significant difference between the groups. Figure 2 presents the mean SF-36 domain scores for patients grouped by disease and degree of blood pressure control. The control group patients reported the highest domain scores. Hypertensive patients whose blood pressure was Ͻ140/90 mm Hg reported higher domain scores than those whose blood pressure was not controlled, or у140/90 mm Hg.
Discussion
In this study, treated hypertensive patients reported more symptoms and related distress, as well as lower physical and social but not emotional HQL domains, as compared to normal controls. Also observed was that treated hypertensive patients whose systolic and/or diastolic blood pressures were over 140/90 mm Hg reported more symptoms and lower HQL than treated hypertensive patients whose blood pressure was controlled. Because this is a cross-sectional study, we cannot comment on causality between symptoms and HQL, but simply describe the possible relationship between the two. Based on these findings, clinicians can anticipate that hypertensive patients receiving drug therapy, especially those with uncontrolled blood pressure, will present with symptoms more often, with greater related distress, and with associated reduction in HQL.
The findings of this study are consistent with the model of the relationship between symptoms and HQL/functional status described by Wilson and Clearly. 12 According to the model, HQL or health status is attributable to symptoms associated with disease and related treatment, modified by patients' personal and environmental characteristics. We hypothesised that the SF-36 domains most affected would be those that represent physical and mental activities likely to be affected by the disease hypertension and antihypertensive related symptoms. However, differences were observed almost exclusively in the physical rather than emotional domains.
More hypertensive group patients reported breathing problems, dizziness, flushing/constipation, sexual problems, increased thirst, increased urination, and weariness than control group patients, all symptoms associated with common antihypertensive medications as well as hypertension. 2, [17] [18] [19] [20] [21] [22] [23] Some of the same frequently reported symptoms were also associated with significantly more distress among the hypertensive patients, such as breathing problems, dizziness, flushing/constipation, increased urination, and weariness. These symptoms may influence the SF-36 domains such as general health, physical functioning, vitality, and the physical summary score. The domains assessing human interaction such as social functioning and role-physical were also significantly lower in the hypertensive group, possibly related to the effects of symptoms.
Evaluating symptoms reported by patients in clinical practice is a complex task. In a hypertensive population, it is often difficult to determine whether symptoms or changes in health status described by patients are caused by the high blood pressure, the medication, the effect of labelling, or some unrelated cause. Results of previous studies examining symptoms and HQL among hypertensive patients have been mixed. Studies have shown no difference in symptoms between hypertensive and non-hypertensive patients, 24, 25 whereas others have reported more symptoms and impaired well-being compared with normotensive control patients. [2] [3] [4] [5] [6] [7] The findings of the present study regarding the differences in HQL between the hypertensive patients and the normal controls is consistent with previous populationbased studies. 2, [26] [27] [28] [29] [30] These studies, however, did not simultaneously measure disease-specific symptoms and HQL.
Symptoms associated with hypertension may be due to elevated blood pressure, the effects of medications, or the psychological effects of being diagnosed with hypertension (labelling). A direct effect of elevated blood pressure on symptoms is suggested in our study and has been reported in the literature, 31 with an increase in symptoms and reduction in HQL seen in patients with uncontrolled blood pressure. Symptoms caused by medications are widely recognised clinically as well as in previous studies. 6, 19, 32, 33 The labelling effect may impair the general well being of hypertensive patients. Studies have documented that symptoms of undiagnosed hypertensive patients are similar to normotensives, 34 and that when the diagnosis is known, assumption of the sick role leading to behaviour such as increased work absenteeism occurs. 35 There was no direct assessment of the labelling effect undertaken in the present study. However, the average length of time since diagnosis of hypertension was over 16 years, a long enough time to expect many patients to adjust their beliefs and attitudes about their disease.
There are several limitations of this study based on its design and subject. Hypertensive patients used for this study were without other symptomatic diseases and may not be representative of many hypertensive patients. Hypertensive patients often have multiple chronic diseases such as dyslipidaemia, arthritis, diabetes, as well as end-organ damage. The influence of multiple diseases and related treatments will likely have a cumulative effect on the patient's symptoms and HQL status. The overall burden of illness may be a better term to characterise the influence of a constellation of disease states and treatments on patients' symptom and HQL status.
Another study limitation was the method by which patients were screened for inclusion. Using medical records exposes the design to the lack of documentation by health care providers. Potentially, patients with early left ventricular dysfunction or other diseases may have been included, conditions which may have altered patients' symptom and HQL reporting.
Lastly, the results may not necessarily be extrapolated to patient populations demographically unlike the study population. The race of the clinic population served by the university medical centre is predominantly white. Further work with the proper sampling of minority patients is necessary to accurately describe symptoms and HQL, as well as causative relationships between symptoms and HQL.
Conclusions
Hypertensive patients receiving antihypertensive medications report more symptoms and lower HQL, than patients with no other diseases or drug treatments. Further, hypertensive patients whose blood pressure is у140/90 mm Hg reported more symptoms, more distress, and lower HQL than hypertensives with controlled blood pressure or relatively healthy non-hypertensives. Clinicians following patients taking antihypertensive medications must be aware that many symptoms, although similar in prevalence to the general population, may be more distressful and have a greater influence on the patient's perceived HQL and functional status. 
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Appendix 1: Symptom distress checklist factors and component items
Comparisons of symptom frequency between hypertensive with medication and control groups
